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ultiple Myeloma in a 50-Year-Old with an HLA-Identical SiblingA 50-year-old, otherwise healthy man was recently diagnosed with symptomatic Ig G kappa multiple
myeloma. On initial evaluation, he had a serum M spike of 6.0 g/dL and beta2 microglobulin of 4.0 mg/L
(Stage II by the International Staging System). Interphase cytogenetics were not performed. He has achieved
a good response, with a serumM spike of 0.5 g/dL after 4 cycles of thalidomide plus dexamethsone. Therapy
was tolerated well with minimal side effects. He has an HLA-identical sibling.
What would you recommend next?
● Continued thalidomide and dexamethasone for several cycles beyond CR, then watchful waiting.
● A single autologous transplant.
● A double (tandem) autologous transplant.
● An autologous transplant followed by a reduced intensity conditioning allogeneic transplant.
● An allogeneic transplant (myeloablative or reduced intensity conditioning).
● Observation.
t
(
m
n
p
c
m
n
b
a
g
ﬁ
t
p
t
h
m
d
d
l
r
c
w
p
m
dEADER RESPONSES
In a recent issue of the ASBMT eNEWS, readers
ere presented with the above Clinical Challenge and
nvited to use an on-line poll to recommend a course
f treatment. The reader recommendations for ther-
py were:
46% An autologous transplant followed by a
reduced intensity conditioning allogeneic
transplant.
33% A single autologous transplant.
8% Continued thalidomide and dexamethasone
for several cycles beyond complete remis-
sion, then watchful waiting.
8% An allogeneic transplant (myeloablative or
reduced intensity conditioning).
5% A double (tandem) autologous transplant.
OMMENTARY
Until recently, treatment recommendations for
atients with newly diagnosed chemoresponsive my-
loma were straightforward: upfront single autologous
ransplantation, given randomized controlled trial
RCT) data indicating overall survival (OS) and pro-
ression-free survival (PFS) beneﬁt [1]. However, a
ecent meta-analysis of all RCTs assessing single au-
ologous transplantation compared to nontransplant
standard dose therapy” (SDT), indicates signiﬁcant
FS beneﬁt but no OS beneﬁt with upfront autotrans-
lantation [2]. tFor those choosing SDT, the optimal regimen and
reatment duration remain uncertain. Novel agents
thalidomide, lenalidomide, bortezomib; with dexa-
ethasone) are preferred [3-5]. Maintenance with a
ovel agent therapy is often continued until disease
rogression or relapse. Randomized data, albeit in the
ontext of tandem autologous transplantation, docu-
ented PFS and possibly OS beneﬁt with mainte-
ance thalidomide [6,7].
Tandem autologous transplantation resulted in
etter OS and PFS than chemotherapy in one RCT,
nd additional studies are pending [8]. Beneﬁt was
reatest for patients with a suboptimal response to the
rst transplant. Given this patient’s excellent response
o induction therapy, it is unlikely tandem autotrans-
lants would be necessary.
Up-front allogeneic transplantation offers a cura-
ive option for myeloma, but a risk of graft-versus-
ost disease (GVHD) and increased treatment-related
ortality (TRM), particularly with myeloablative con-
itioning, although outcomes have improved [9]. Re-
uced-intensity conditioning (RIC) is associated with
ower TRM, comparable GVHD, but higher relapse
ates [10,11]. Up-front allotransplantation may be
onsidered in the context of a clinical trial.
Results of up-front autologous transplantation
ith sequential RIC allotransplantation have varied,
artly for technical reasons. A study of “high-risk”
yeloma (elevated 2 microglobulin, chromosome 13
eletion) adding antithymocyte globulin to RIC allo-
ransplantation documented low GVHD rates, but no
1247
s
t
d
R
[
r
a
t
a
d
J
D
D
B
R
1
1
1
1
J. Koreth1248urvival beneﬁt compared to tandem autotransplanta-
ion [12]. Another RCT utilizing 2 Gy irradiation con-
itioning described OS and PFS beneﬁt with sequential
IC allotransplantation, with 36% PFS at 38 months
13]. Additional RCTs are ongoing, but I would not
ecommend this approach outside of a clinical trial.
Currently, I would recommend up-front single
utologous transplantation for this patient in an effort
o extend PFS. Continuing SDT is also reasonable,
lbeit with uncertainty regarding optimal regimen and
uration.
ohn Koreth, MBBS, DPhil
ana Farber Cancer Institute
ivision of Hematologic Malignancies
oston, Massachusetts
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